Artios Pharma Ltd., a cancer treatment developer based in the U.K. and New York, closed a $153 million Series C round co-led by Omega Funds and TCG Crossover. New investors including Avidity Partners, Invus, Deep Track Capital, Sofinnova Partners, RTW Investments and Soleus Capital also participated in the funding, along with existing backers Arix Bioscience, SV Health Investors, Andera Partners, LSP, M Ventures, Pfizer Ventures, IP Group and Novartis Venture Fund. Omega Funds’ Michelle Doig and TCG X’s Chen Yu will join the company’s board.
SonderMind Inc., a Denver-based behavioral health marketplace, completed a $150 million Series C round. Drive Capital and Premji Invest co-led the investment, which included participation from General Catalyst, Partners Group, Smash Ventures, Kickstart Fund and F-Prime Capital. Drive Capital’s Molly Bonakdarpour will join the board.
Ring Therapeutics, a Cambridge, Mass.-based gene therapy startup, secured $117 million in Series B financing from investors including Flagship Pioneering, Invus, Altitude Life Science Ventures, Partners Investment, UPMC Enterprises and funds and accounts advised by T. Rowe Price Associates Inc.
Strata Oncology Inc., an Ann Arbor, Mich.-based provider of precision medicine research and care for cancer patients, snagged $90 million in Series C funding led by Wellington Management. Returning backers Pfizer Ventures, Merck Global Health Innovation Fund, Arboretum Ventures, Deerfield Management, Baird Capital and Renaissance Venture Capital also joined the round, in addition to new investors Cormorant Asset Management, Monashee Investment Management and Highside Capital Management.
Elvie, a U.K.-based developer of products for women including a silent wearable breast pump and a pelvic floor strengthening device, picked up $80 million in Series C financing. BGF led the investment, which saw additional participation from funds and accounts managed by BlackRock Private Equity Partners, Hiro Capital, Westerly Winds, Octopus Ventures and IPGL. BGF’s Daina Spedding and BlackRock’s Persefoni Noulika will join the board.
MiRus LLC, a Marietta, Ga.-based developer of medical alloys to make surgeries less invasive and implants safer and more durable, nabbed $65 million in funding. Mammoth Scientific, which earlier this month launched a $100 million fund, led the round.
Aristea Therapeutics, a San Diego-based startup developing novel therapies to treat serious inflammatory orphan diseases, grabbed $63 million in Series B funding. Lead investor Fidelity Management & Research Co. was joined by Novo Holdings, Arena Pharmaceuticals and funds managed by Tekla Capital Management in the round. Loretta Tse, vice president at Tekla Capital, will join Aristea’s board.
BioIntelliSense Inc., a remote patient monitoring provider, closed a $45 million Series B round. Chimera Investments led the funding, which included contributions from 7wire Technology Partners, CU Healthcare Innovation Fund and others.
veda, a Madison, Wis.-based startup whose technology automates healthcare administration, collected a $45 million Series B round. Oak HC/FT led the financing, with Managing Partner Andrew Adams joining the board.
IgGenix Inc., a South San Francisco, Calif.-based startup developing therapies for people impacted by food allergies, raised $25 million in Series A1 funding. Khosla Ventures and Matthias Westman co-led the new investment, which included participation from Alexandria Venture Investments, ShangBay Capital and AllerFund.
MedRhythms, a Portland, Maine-based developer of digital therapeutics to measure and improve walking for patients with a neurologic injury or disease, secured $25 million in Series B financing co-led by Morningside Ventures and Advantage Capital.
|